Start Your Search
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Presentations: 1
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
P083 - Efficacy of EGFR-TKIs in Patients Harboring EGFR Mutations with Non-Adenocartinoma Histology (ID 223)
00:00 - 00:00 | Author(s): O Yuko
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have substantial anti-tumor activity for NSCLC harboring EGFR sensitizing mutations. Adenocarcinoma (ADC) is the most common histological subtypes in patients with NSCLC harboring EGFR mutations. Whereas, EGFR mutations are occasionally observed in other histological subtypes of NSCLC. However, little is known about the efficacy of EGFR-TKIs in patients with non-adenocarcinoma harboring EGFR mutations.
We retrospectively analyzed 1467 patients with EGFR mutated NSCLC and treated with EGFR-TKIs between January 2008 and August 2017 from 11 institutions in Japan. We investigated the efficacy of EGFR-TKIs in patients with non-ADC NSCLC, compared with patients with EGFR mutated ADC. The protocol of this study was approved by institutional review board in each institution, and this study was registered in trial registration with preplanned statistical protocol (Clinical Trial information: UMIN000030121).
Finally, 1400 patients were analyzed, 68 patients with non-ADC, including 25 in squamous cell carcinoma, 4 in large cell carcinoma, 5 in pleomorphic carcinoma and 34 in others. Among 63 non-ADC patients, 57 patients received first generation TKIs and 10 patients received second generation TKI (there is some overlapping). The ORR of EGFR-TKIs was 60.0% in non-ADC and 64.2% in ADC, respectively. The median time to treatment failure were 7.4 months (95% CI, 4.7-10.2) in non-ADC and 11.1 months (95% CI, 10.3-12.0) in ADC (p=0.008). The median overall survival were 16.8 months (95% CI, 12.1-21.5) in non-ADC and 33.3 months (95% CI, 30.3-36.4) in ADC (p<0.001).
EGFR-TKIs are less effective in EGFR mutated patients with non-ADC than ADC, nevertheless EGFR-TKIs has certain clinical benefit against EGFR mutated non-ADC.